Editorial: on the road towards treatment of gastroparesis-accelerating, but do we get closer? Authors' reply.

Tytuł:: Editorial: on the road towards treatment of gastroparesis-accelerating, but do we get closer? Authors' reply.
Autorzy:: Kuo B; Massachusetts General Hospital, Boston, MA, USA.
Barnes CN; Theravance Biopharma US, Inc., South San Francisco, CA, USA.
Nguyen DD; Theravance Biopharma US, Inc., South San Francisco, CA, USA.
Shaywitz D; Theravance Biopharma US, Inc., South San Francisco, CA, USA.
Grimaldi M; Alfasigma S.p.A., Bologna, Italy.
Renzulli C; Alfasigma S.p.A., Bologna, Italy.
Canafax D; Theravance Biopharma US, Inc., South San Francisco, CA, USA.
Parkman HP; Temple University School of Medicine, Philadelphia, PA, USA.
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Jul; Vol. 54 (2), pp. 185-186.
Typ publikacji:: Editorial; Research Support, Non-U.S. Gov't; Comment
Język:: English
Imprint Name(s):: Publication: Oxford : Wiley-Blackwell
Original Publication: [Oxford, OX] : Blackwell Scientific Publications, [c1987-
MeSH Terms:: Gastroparesis*/therapy
Humans
References:: Wuestenberghs F, Gourcerol G. Editorial: on the road toward treatment of gastroparesis - accelerating, but do we get closer? Aliment Pharmacol Ther. 2021;54:183-184.
Kuo B, Barnes CN, Nguyen DD, et al. Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 study. Aliment Pharmacol Ther. 2021;53:1090-1097.
Center for Drug Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services. Gastroparesis: Clinical evaluation of drugs for treatment. Guidance for industry. Draft guidance. Clinical/Medical. Revision 1. August 2019. https://www.fda.gov/media/129880/download. Accessed April 8, 2021.
The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study (DIGEST). https://www.clinicaltrials.gov/ct2/show/NCT02267525. Accessed April 8, 2021.
Abell T, Kuo B, Esfandyari T, et al. Velusetrag improves gastroparesis both in symptoms and gastric emptying in patients with diabetic or idiopathic gastroparesis in a 12-week global phase 2b study. Gastroenterology. 2019;156:S164.
Abell T, Kuo B, Esfandyari T, et al. Efficacy of veluestrag treatment in patients with idiopathic gastroparesis: Subgroup analysis of a phase 2b study. United European Gastroenterol J. 2019;7:77-78.
Entry Date(s):: Date Created: 20210625 Date Completed: 20210809 Latest Revision: 20210809
Update Code:: 20240105
DOI:: 10.1111/apt.16395
PMID:: 34170530
: Raport

Pełny tekst

Comment on: Aliment Pharmacol Ther. 2021 May;53(10):1090-1097. (PMID: 33811761)
Comment on: Aliment Pharmacol Ther. 2021 Jul;54(2):183-184. (PMID: 34170529)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja